An Investigation on a Novel Anti-tumor Fusion Peptide of FSH33-53-IIKK.
A novel fusion peptide FSH33-53-IIKK was designed and expected to combine the follicle stimulating hormone receptor (FSHR) targeting and tumor toxicity. In vitro and in vivo study showed the anti-tumor activity of FSH33-53-IIKK was enhanced compared to that of IIKK only. FSH33-53-IIKK could inhibit the growth of tumor via apoptosis and autophagy pathways. In summary, combining the tumor marker-target peptide and anti-tumor peptide together may be an efficient way to search for better anti-tumor candidates.
1. Key Laboratory of Nuclear Medicine, Ministry of Health, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, China.
Runlin
R
Yang
2. School of Pharmaceutical Science, Zhengzhou University, Zhengzhou 450000, China.
Ping
P
Liu
1. Key Laboratory of Nuclear Medicine, Ministry of Health, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, China.
Donghui
D
Pan
2. School of Pharmaceutical Science, Zhengzhou University, Zhengzhou 450000, China.
Pengjun
P
Zhang
3. The First School of Clinical Medicine, Nanjing Medical University, Nanjing 210029, China.
Zhicheng
Z
Bai
1. Key Laboratory of Nuclear Medicine, Ministry of Health, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, China.
Yuping
Y
Xu
1. Key Laboratory of Nuclear Medicine, Ministry of Health, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, China.
Lizhen
L
Wang
1. Key Laboratory of Nuclear Medicine, Ministry of Health, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, China.
Junjie
J
Yan
4. Department of Medical Physics, University of Wisconsin, Madison, WI 53705, USA.
Yongjun
Y
Yan
5. Department of Nuclear Medicine, Hua Shan Hospital, Fudan University, Shanghai 200040, China.
Xingdang
X
Liu
1. Key Laboratory of Nuclear Medicine, Ministry of Health, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, China.; 2. School of Pharmaceutical Science, Zhengzhou University, Zhengzhou 450000, China.; 3. The First School of Clinical Medicine, Nanjing Medical University, Nanjing 210029, China.
Min
M
Yang
Anti-tumor; Apoptosis; Autophagy; FSH33-53-IIKK; FSHR; Fusion peptide